Long-term effects of JL 13, a potential atypical antipsychotic, on ionotropic glutamate receptors

Journal of Molecular Neuroscience

Volumn 32, Issue 3, 2007, Pages 192-198

  Tarazi, Frank I ^a,b,d   Moran Gates, Taylor ^a   Gardner, Matthew P ^a   Graulich, Amaury ^c   Lamy, Cédric ^c   Liégeois, Jean François ^c  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF LIÈGE   (Belgium)

^d MCLEAN HOSPITAL   (United States)

Author keywords

Antipsychotic drugs; Autoradiography; Caudate putamen; Glutamate receptors; Hippocampus

Indexed keywords

5 (4 METHYLPIPERAZIN 1 YL) 8 CHLOROPYRIDO[2,3 B]BENZOXAZEPINE FUMARATE; AMPA RECEPTOR; ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; HALOPERIDOL; IONOTROPIC RECEPTOR; JL 13; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NEUROLEPTIC AGENT; OLANZAPINE; RISPERIDONE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; AUTORADIOGRAPHY; CAUDATE NUCLEUS; CONTINUOUS INFUSION; CONTROLLED STUDY; DRUG EFFECT; ENTORHINAL CORTEX; EXTRAPYRAMIDAL SYMPTOM; FOREBRAIN; HIPPOCAMPUS; MALE; NONHUMAN; OSMOTIC MINIPUMP; PSYCHOPHARMACOLOGY; PUTAMEN; QUANTITATIVE ANALYSIS; RAT; RECEPTOR BINDING; RECEPTOR DOWN REGULATION; RISK REDUCTION;

ANIMALS; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; ANTIPSYCHOTIC AGENTS; AUTORADIOGRAPHY; BENZODIAZEPINES; BRAIN; CAUDATE NUCLEUS; CEREBRAL CORTEX; CLOZAPINE; HALOPERIDOL; HIPPOCAMPUS; MALE; OXAZEPINES; PIPERAZINES; PUTAMEN; PYRIDINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, AMPA; RECEPTORS, N-METHYL-D-ASPARTATE; RISPERIDONE; TRITIUM;

RATTUS;

EID: 35348816730     PISSN: 08958696     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12031-007-0034-3     Document Type: Article

References (34)

1. Aghajanian, G. K., & Marek, G. J. (2000). Serotonin model of schizophrenia: Emerging role of glutamate mechanisms. Brain Research Reviews, 31, 302-312.
2. Baldessarini, R. J., & Tarazi, F. I. (2005). Pharmacotherapy of psychosis and mania. In L. L. Brunton, J. S. Lazo, & K. L. Parker (Eds.), Goodman and Gilman's the pharmacological basis of therapeutics (pp. 461-500). New York: McGraw-Hill.
3. Boegman, R. J., & Vincent, S. R. (1996). Involvement of adenosine and glutamate receptors in the induction of c-fos in the striatum by haloperidol. Synapse, 22, 70-77.
4. Bruhwyler, J., Liégeois, J.-F., Bergman, J., Carey, G., Goudie, A., Taylor, A., et al. (1997). JL13, a pyridobenzoxazepine compound with potential atypical antipsychotic activity: A review of its behavioral properties. Pharmacoligical Research, 36, 255-264.
5. 2+/calmodulin-dependent kinase II in prefrontal cortical pyramidal neurons. Journal of Biological Chemistry, 277, 36553-36562.
6. Carlsson, A., Waters, N., Holm-Waters, S., Tedroff, J., Nilsson, M., & Carlsson, M. L. (2001). Interactions between monoamines, glutamate, and GABA in schizophrenia: New evidence. Annual Review of Pharmacology and Toxicology, 41, 237-260.
7. Casey, D. E., Bruhwyler, J., Delarge, J., Géczy, J., & Liégeois, J.-F. (2001). The behavioral effects of acute and chronic JL 13, a putative antipsychotic, in Cebus non-human primates. Psychopharmacology, 157, 228-235.
8. Conn, P. J., & Pin, J. P. (1997). Pharmacology and functions of metabotropic glutamate receptors. Annual Review of Pharmacology and Toxicology, 37, 205-237.
9. Ellenbroek, B. A., & Liégeois, J.-F. (2003). JL 13, an atypical antipsychotic: A preclinical review. CNS Drug Reviews, 9, 41-56.
10. Ellenbroek, B. A., Liégeois, J.-F., Bruhwyler, J., & Cools, A. R. (2001). Effects of JL13, a pyridobenzoxazepine with potential atypical antipsychotic activity, in animal models for schizophrenia. Journal of Pharmacology and Experimental Therapeutics, 298, 386-391.
11. Gao, X. M., Sakai, K., Roberts, R. C., Conley, R. R., Dean, B., & Tamminga, C. A. (2000). Ionotropic glutamate receptors and expression of N-methyl-D-aspartate receptor subunits in sub-regions of human hippocampus: Effects of schizophrenia. American Journal of Psychiatry, 157, 1141-1149.
12. Goff, D. C., & Coyle, J. T. (2001). The emerging role of glutamate in the pathophysiology and treatment of schizophrenia. American Journal of Psychiatry, 158, 1367-1377.
13. Goff, D. C., Leahy, L., Berman, I., Posever, T., Herz, L., Leon, A. C., et al. (2001). A placebo-controlled pilot study of the ampakine CX516 added to clozapine in schizophrenia. Journal of Clinical Psychopharmacology, 21, 484-487.
14. Hollmann, M., & Heinemann, S. (1994). Cloned glutamate receptors. Annual Review of Neuroscienceci, 17, 31-108.
15. Invernizzi, R., Garavaglia, C., & Samanin, R. (2000). JL13, a pyridobenzoxazepine compound with potential atypical antipsychotic activity, increases extracellular dopamine in the prefrontal cortex, but not in the striatum and the nucleus accumbens of rats. Naunyn-Schmiedeberg's Archives of Pharmacology, 361, 298-302.
16. Javitt, D. C., & Zukin, S. R. (1991). Recent advances in the phencyclidine model of schizophrenia. American Journal of Psychiatry, 148, 1301-1308.
17. Krieckhaus, E. E., Donahoe, J. W., & Morgan, M. A. (1992). Paranoid schizophrenia may be caused by dopamine hyperactivity of CA1 hippocampus. Biological Psychiatry, 31, 560-570.
18. McCoy, L., Cox, C., & Richfield, E. K. (1996). Chronic treatment with typical and atypical antipsychotics increases the AMPA-preferring form of AMPA receptor in rat brain. European Journal of Pharmacology, 318, 41-45.
19. McCoy, L., Cox, C., & Richfield, E. K. (1998). Antipsychotic drug regulation of AMPA receptor affinity states and GluR1, GluR2 splice variant expression. Synapse, 28, 195-207.
20. Meador-Woodruff, J. H., & Healy, D. J. (2000). Glutamate receptor expression in schizophrenic brain. Brain Research Reviews, 31, 288-294.
21. Moran-Gates, T., Massari, C., Graulich, A., Liégeois, J. F., & Tarazi, F. I. (2006). Long-term effects of JL 13, a potential atypical antipsychotic, on rat dopamine and serotonin receptor subtypes. Journal of Neuroscience Research, 84, 675-682.
22. Ozawa, S., Kamiya, H., & Tsuzuki, K. (1998). Glutamate receptors in the mammalian central nervous system. Progress in Neurobiology, 54, 581-618.
23. Paxinos, F., & Watson, C. (1982). The rat brain in stereotaxic coordinates. New York: Academic Press.
24. Riva, M. A., Tascedda, F., Lovati E., & Racagni, G. (1997). Regulation of NMDA receptor subunit messenger RNA levels in the rat brain following acute and chronic exposure to antipsychotic drugs. Molecular Brain Research, 50, 136-142.
25. Schmidt, W. J., & Bubser, M. (1989). Anticataleptic effects of the N-methyl-D-aspartate antagonist MK-801 in rats. Pharmacology, Biochemistry and Behavior, 32, 621-623.
26. Spurney, C. F., Baca, S. M., Murray, A. M., Jaskiw, G. E., Kleinmann, J. E., & Hyde, T. M. (1999). Differential effects of haloperidol and clozapine on ionotropic glutamate receptors in rats. Synapse, 34, 266-276.
27. Tarazi, F. I., Baldessarini, R. J., Kula, N. S., & Zhang, K. (2003). Long-term effects of olanzapine, risperidone, and quetiapine on ionotropic glutamate receptor types: Implications for antipsychotic drug treatment. Journal of Pharmacology and Experimental Therapeutics, 306, 1145-1151.
28. Tarazi, F. I., Florijn, W. J., & Creese, I. (1996). Regulation of ionotropic glutamate receptors following subchronic and chronic treatment with typical and atypical antipsychotics. Psychopharmacology, 128, 371-379.
29. Tarazi, F. I., Zhang, K., & Baldessarini, R. J. (2000). Effects of nigrostriatal dopamine denervation on ionotropic glutamate receptors in rat caudate-putamen. Brain Research, 881, 69-72.
30. Tascedda, F., Blom, J. M., Brunello, N., Zolin, K., Gennarelli, M., Colzi, A., et al. (2001). Modulation of glutamate receptors in response to the novel antipsychotic olanzapine in rats. Biological Psychiatry, 50, 117-122.
31. Tascedda, F., Lovati, E., Blom, J. M., Muzzioli, P., Brunello, N., Racagni, G., et al. (1999). Regulation of ionotropic glutamate receptors in the rat brain in response to the atypical antipsychotic seroquel (quetiapine fumarate). Neuropsychopharmacology, 21, 211-217.
32. Tsai, G., & Coyle, J. T. (2002). Glutamatergic mechanisms in schizophrenia. Annual Review of Pharmacology and Toxicology, 42, 165-179.
33. Wullner, U., Testa, C. M., Catania, M. V., Young, A. B., & Penney, J. B. (1994). Glutamate receptors in striatum and substantia nigra: Effects of medial forebrain bundle lesions. Brain Research, 645, 98-102.
34. Yoshida, Y., Ono, T., Kizu, A., Fukushima, R., & Miyagishi, T. (1991). Striatal N-methyl-D-aspartate receptors in haloperidol-induced catalepsy. European Journal of Pharmacology, 203, 173-180.